Education, Science, Technology, Innovation and Life
Open Access
Sign In

Progress of Chinese and Western medicine research on cognitive dysfunction due to cerebral small vessel disease

Download as PDF

DOI: 10.23977/medcm.2024.060203 | Downloads: 6 | Views: 255

Author(s)

Yun Yedong 1, Yin Jun 1, Hu Zhouyuan 1, Yan Yongmei 2

Affiliation(s)

1 Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, 712046, China
2 Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, China

Corresponding Author

Yan Yongmei

ABSTRACT

Cerebral small vascular disease is a common clinical neurological degenerative disease, is an important risk factors of stroke, cognitive impairment and death. CSVD can be acute onset, manifested as cerebral hemorrhage or ischemic stroke, but most of its onset hidden, and slow progress, some of patients with cognitive dysfunction can be manifested as dementia, memory loss, cognitive decline, etc, serious harm to the health of the elderly and the quality of life. There is a lack of early diagnosis methods and intervention measures for this disease, so to clarify the current situation and future development direction of TCM and western medicine research with cognitive impairment can provide new ideas for basic and clinical research. This paper reviews the current situation and new progress of the diagnosis and treatment of CSVD cognitive impairment.

KEYWORDS

Cerebral small vessel disease; cognitive impairment; Chinese medicine; research progress

CITE THIS PAPER

Yun Yedong, Yin Jun, Hu Zhouyuan, Yan Yongmei, Progress of Chinese and Western medicine research on cognitive dysfunction due to cerebral small vessel disease. MEDS Chinese Medicine (2024) Vol. 6: 24-30. DOI: http://dx.doi.org/10.23977/medcm.2024.060203.

REFERENCES

[1] Bos D, Wolters FJ, Darweesh SKL, et al.Cerebral small vessel disease and the risk of dementia:A systematic review and meta⁃analysis of population⁃based evidence[J].Alzheimers Dement, 2018, 14(11):1482⁃1492.
[2] Brown R, Benveniste H, Black SE, et al.Understanding the role of the perivascular space in cerebral small vessel disease[J].Cardiovasc Res, 2018, 114(11):1462⁃1473.
[3] Rensma S, Sloten TV, Launer L, et al.Cerebral small vessel disease and risk of stroke, dementia, depression, and all ⁃cause mortality:a systematic review and Meta ⁃analysis [J].Neurosci Biobehav Rev, 2018, 90:164⁃173.
[4] Søndergaard CB, Nielsen JE, Hansen CK, et al. Hereditary cerebral small vessel disease and stroke [J].Clin Neurol Neurosurg, 2017, 155:45-57.
[5] Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications[J]. The Lancet Neurology, 2019, 18 (7): 684-696.
[6] Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging [J]. The Lancet Neurology, 2013, 12(5): 483-497.
[7] Wadlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration[J]. The Lancet Neurology, 2013, 12(8): 822-838.
[8] Kwon SM, Choi KS, Yi HJ, et al. Impact of brain atrophy on 90-day functional outcome after moderate-volume basal ganglia hemorrhage [J]. Sci Rep, 2018, 8(1): 1-6.
[9] Ryu WS, Woo SH, Schellingerhout D, et al. Stroke outcomes are worse with larger leukoaraiosis volumes[J]. Brain, 2017, 140(1): 158-170.
[10] Zhang X, Tang Y, Xie Y, et al. Total magnetic resonance imaging burden of cerebral small-vessel disease is associated with post-stroke depression in patients with acute lacunar stroke[J]. European Journal of Neurology, 2017, 24(2): 374-380
[11] Hilal S, Mok V, Youn YC, et al. Prevalence, risk factors and consequences of cerebral small vessel diseases: data from three Asian countries[J]. Journal of Neurology, Neurosurgery & Psychiatry, 2017, 88(8): 669-674.
[12] Khan U, Porteous L, Hassan A, et al. Risk factor profile of cerebral small vessel disease and its subtypes[J]. Journal of Neurology, Neurosurgery & Psychiatry, 2007, 78(7): 702-706.
[13] Zhang CE, Wong SM, Vanedhaar HJ, et al. Blood-brain barrier leakage is more widespread in patients with cerebral small vessel disease [J]. Neurology, 2017, 88(5): 426-432.
[14] Beck C, Kruetzelmann A, Forkert ND, et al. A simple brain atrophy measure improves the prediction of malignant middle cerebral artery infarction by acute DWI lesion volume[J]. Journal of Neurology, 2014, 261: 1097-1103.
[15] Whitwell JL, Jack CR, Parisi JE, et al. Rates of cerebral atrophy differ in different degenerative pathologies[J]. Brain, 2007, 130(4): 1148-1158.
[16] Sala S, Agosta F, Pagani E, et al. Microstructural changes and atrophy in brain white matter tracts with aging[J]. Neurobiology of Aging, 2012, 33(3): 488-498.
[17] Nitkunan A, Lanfranconi S, Charlton RA, et al. Brain atrophy and cerebral small vessel disease: a prospective follow-up study [J]. Stroke, 2011, 42(1): 133-138.
[18] Van Middelaar T, Argillander TE, Schreuder FH, et al. Effect of antihypertensive medication on cerebral small vessel disease: a systematic review and meta-analysis[J]. Stroke, 2018, 49(6): 1531-1533.
[19] Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med, 2013, 369: 11-19.
[20] Mok V, Kim JS. Prevention and management of cerebral small vessel disease[J]. Journal of Stroke, 2015, 17(2): 111-122.
[21] Charidimou A, Pasi M, Fiorelli M, et al. Leukoaraiosis, cerebral hemorrhage, and outcome after intravenous thrombolysis for acute ischemic stroke: a meta-analysis[J]. Stroke, 2016, 47(9): 2364-2372.
[22] Xiong Y, Wong A, Cavalieri M, et al. Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confluent white matter hyperintensities [J]. Neurotherapeutics, 2014, 11: 606-611.
[23] Amarenco P, Bebavebte O, Goldstein LB, et al. Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes[J]. Stroke, 2009, 40(4): 1405-1409.
[24] Group HPSC. MRC /BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial[J]. The Lancet, 2002, 360(9326): 7-22.
[25] Ma Jingya, Liu Xinmin, Jin Zhe-hsiung, et al. Progress in traditional Chinese medicine to improve cognitive dysfunction [J]. Chinese Journal of Traditional Chinese Medicine Information, 2013, 20 (9): 104-107.
[26] Liu Junyi, Yin Jingyun, and Chen Changbao. Efficacy of Puhuoxue decoction in mild cognitive impairment after ischemic stroke [J]. New Traditional Chinese Medicine, 2012 (1): 19-20.
[27] Yuan Bin, Chen Juan, Sun Yong'an. Randomized controlled double blind clinical trial of stanche total glycoin capsules for neuropsychiatric symptoms of dementia [J]. Modern drug application in China, 2009, 3 (18): 30-32.
[28] Zhang Hua, Wang Jun, Zhao Dongjie. Efficacy of tonifying puzzle granules in the treatment of mild cognitive dysfunction after ischemic stroke [J]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine, 2012, 22 (6): 445-446.
[29] Fu Hong, Wang Xuemei, Liu Gengxin, et al. Magnetic resonance study of memory function and hippocampus volume in patients with mild cognitive impairment [J]. Chinese Journal of Integrated Traditional Chinese and Western Medicine, 2006, 26 (12): 1066-1069.
[30] Li Zhijie, Mei Hongbin. Clinical study of Tiandijing pill for treatment of mild cognitive impairment [J]. Hubei Journal of Traditional Chinese Medicine, 2007, 29 (10): 10-12.
[31] Shang Liang, Zhang Jing, Miao Qing, et al. Efficacy of cerebral blood oral solution combined with donepezil in mild to moderate vascular dementia [J]. Journal of Cardiovascular and cerebrovascular Diseases of Integrated Traditional Chinese and Western Medicine, 2015, 13 (1): 107-108.

Downloads: 4729
Visits: 197603

Sponsors, Associates, and Links


All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.